Assessing NODM Patients for Early PDAC Diagnosis: Incidence of NODM Before PDAC Diagnosis and Subsequent PDAC Risk
Cancer Medicine · 2025
DOI: 10.1002/cam4.70878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Satish Munigala und 8 weiteren Autor:innen. Beteiligte Einrichtung: College for Public Health and Social Justice, Saint Louis University, Saint Louis, Missouri, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Diabetes Mellitus. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
New‐Onset Diabetes Mellitus (NODM) is often an early manifestation of pancreatic cancer (Pancreatic Ductal Adenocarcinoma, PDAC). However, there is limited information about (1) the duration prior to PDAC diagnosis when the annual incidence of NODM starts significantly exceeding that in age‐matched controls, (2) the percentage of PDAC patients diagnosed with NODM in the years preceding, and (3) the risk of PDAC following NODM in time when the PDAC risk is significantly higher than in controls.
Methods
Using the nationwide VA database, we evaluated the annual incidence of NODM for 15 years preceding the PDAC diagnosis and in the age‐ and sex‐matched controls (1:5 matching). In the second part, we evaluated the long‐term risk and predictors of PDAC in NODM patients and controls.
Results
The case–control study comprised 8198 PDAC patients and 40,992 matched controls. The higher annual incidence of NODM in PDAC patients was statistically significant up to 15 years before PDAC diagnosis. 69.2% of PDAC patients had NODM in the preceding 15 years versus 38.0% of controls. PDAC risk in the 15 years following NODM was 0.60% compared to 0.13% in the controls (aHR 3.83, 95% CI 3.68–3.98, p < 0.001). The risk of PDAC is more pronounced in the 1 year following NODM (aHR 9.07, 95% CI 8.33–9.87) than the subsequent 5 years (aHR 2.98, 95% CI 2.82–3.15).
Conclusion
NODM pre‐dates PDAC diagnosis in most patients with PDAC. Further evaluation of NODM patients for PDAC has the potential to become a feasible strategy for diagnosing more early‐stage resectable PDACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College for Public Health and Social Justice, Saint Louis University, Saint Louis, Missouri, USA.
- Department of Internal Medicine, Washington University in St. Louis, Saint Louis, Missouri, USA.
- Clinical Epidemiology Center, Research and Education Service, VA Saint Louis, Health Care System, Saint Louis, Missouri, USA.
- Department of Health and Clinical Outcomes Research, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
- Advanced HEAlth Data (AHEAD) Institute, Saint Louis University, Saint Louis, Missouri, USA.
- Department of Epidemiology & Biostatistics, College for Public Health and Social Justice, Saint Louis University, Saint Louis, Missouri, USA.
ORCID-Profile: Satish Munigala
Zitieren
APA
Munigala, S., Bowe, B., Subramaniam, D. S., Xian, H., Gowda, A. N., Sheth, S. G., Chhabra, R., Burroughs, T. E., & Agarwal, B. (2025). Assessing NODM Patients for Early PDAC Diagnosis: Incidence of NODM Before PDAC Diagnosis and Subsequent PDAC Risk. Cancer Medicine. https://doi.org/10.1002/cam4.70878
Vancouver
Munigala S, Bowe B, Subramaniam DS, Xian H, Gowda AN, Sheth SG, et al. Assessing NODM Patients for Early PDAC Diagnosis: Incidence of NODM Before PDAC Diagnosis and Subsequent PDAC Risk. Cancer Medicine. 2025. doi:10.1002/cam4.70878
BibTeX
@article{Munigala2025,
author = {Munigala, Satish and Bowe, Benjamin and Subramaniam, Divya S and Xian, Hong and Gowda, Arna N and Sheth, Sunil G and Chhabra, Rajiv and Burroughs, Thomas E and Agarwal, Banke},
title = {Assessing NODM Patients for Early PDAC Diagnosis: Incidence of NODM Before PDAC Diagnosis and Subsequent PDAC Risk},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70878}
}
EUVIMED